Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00044928 |
A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal infection.
Condition | Intervention | Phase |
---|---|---|
Bacterial Infections |
Drug: Piperacillin/Tazobactam |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Randomized, Open-Label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-Abdominal Infection |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Study ID Numbers: | 0910X-101074 |
Study First Received: | September 6, 2002 |
Last Updated: | October 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00044928 |
Health Authority: | United States: Food and Drug Administration |
Abdominal Infections |
Bacterial Infections Penicillanic Acid Tazobactam Piperacillin Piperacillin-tazobactam combination product |
Anti-Infective Agents Anti-Bacterial Agents Communicable Diseases Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Enzyme Inhibitors Infection Pharmacologic Actions |